Switch theme
Sign up to access all valuation multiples
EQL Pharma AB is a pharmaceutical company engaged in developing and selling medicines to pharmacies and hospitals. The products offered by the company include generics and parallel imports. It operates and markets products to Nordic countries of Sweden, Denmark, Finland and Norway.
2006
10
LTM Revenue $40.6M
LTM EBITDA $8.8M
$293M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
EQL Pharma has a last 12-month revenue (LTM) of $40.6M and a last 12-month EBITDA of $8.8M.
In the most recent fiscal year, EQL Pharma achieved revenue of $38.5M and an EBITDA of $6.9M.
EQL Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
See EQL Pharma valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $40.6M | XXX | $38.5M | XXX | XXX | XXX |
| Gross Profit | $17.2M | XXX | $16.1M | XXX | XXX | XXX |
| Gross Margin | 42% | XXX | 42% | XXX | XXX | XXX |
| EBITDA | $8.8M | XXX | $6.9M | XXX | XXX | XXX |
| EBITDA Margin | 22% | XXX | 18% | XXX | XXX | XXX |
| EBIT | $7.5M | XXX | $6.9M | XXX | XXX | XXX |
| EBIT Margin | 18% | XXX | 18% | XXX | XXX | XXX |
| Net Profit | $4.7M | XXX | $4.4M | XXX | XXX | XXX |
| Net Margin | 12% | XXX | 12% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $38.1M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, EQL Pharma's stock price is SEK 85 (or $9).
EQL Pharma has current market cap of SEK 2.5B (or $255M), and EV of SEK 2.8B (or $293M).
See EQL Pharma trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $293M | $255M | XXX | XXX | XXX | XXX | $0.17 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, EQL Pharma has market cap of $255M and EV of $293M.
EQL Pharma's trades at 8.2x EV/Revenue multiple, and 46.3x EV/EBITDA.
Equity research analysts estimate EQL Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
EQL Pharma has a P/E ratio of 53.8x.
See valuation multiples for EQL Pharma and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $255M | XXX | $255M | XXX | XXX | XXX |
| EV (current) | $293M | XXX | $293M | XXX | XXX | XXX |
| EV/Revenue | 7.2x | XXX | 8.2x | XXX | XXX | XXX |
| EV/EBITDA | 33.1x | XXX | 46.3x | XXX | XXX | XXX |
| EV/EBIT | 39.3x | XXX | 48.4x | XXX | XXX | XXX |
| EV/Gross Profit | 17.0x | XXX | n/a | XXX | XXX | XXX |
| P/E | 53.8x | XXX | 64.9x | XXX | XXX | XXX |
| EV/FCF | -12.7x | XXX | -12.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialEQL Pharma's last 12 month revenue growth is 32%
EQL Pharma's revenue per employee in the last FY averaged $3.9M, while opex per employee averaged $0.9M for the same period.
EQL Pharma's rule of 40 is 49% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
EQL Pharma's rule of X is 101% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for EQL Pharma and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 32% | XXX | 32% | XXX | XXX | XXX |
| EBITDA Margin | 22% | XXX | 18% | XXX | XXX | XXX |
| EBITDA Growth | 51% | XXX | 56% | XXX | XXX | XXX |
| Rule of 40 | 49% | XXX | 49% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 101% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $3.9M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.9M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 16% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 3% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 24% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
EQL Pharma acquired XXX companies to date.
Last acquisition by EQL Pharma was XXXXXXXX, XXXXX XXXXX XXXXXX . EQL Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was EQL Pharma founded? | EQL Pharma was founded in 2006. |
| Where is EQL Pharma headquartered? | EQL Pharma is headquartered in Sweden. |
| How many employees does EQL Pharma have? | As of today, EQL Pharma has 10 employees. |
| Is EQL Pharma publicy listed? | Yes, EQL Pharma is a public company listed on STO. |
| What is the stock symbol of EQL Pharma? | EQL Pharma trades under EQL ticker. |
| When did EQL Pharma go public? | EQL Pharma went public in 2024. |
| Who are competitors of EQL Pharma? | Similar companies to EQL Pharma include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of EQL Pharma? | EQL Pharma's current market cap is $255M |
| What is the current revenue of EQL Pharma? | EQL Pharma's last 12 months revenue is $40.6M. |
| What is the current revenue growth of EQL Pharma? | EQL Pharma revenue growth (NTM/LTM) is 32%. |
| What is the current EV/Revenue multiple of EQL Pharma? | Current revenue multiple of EQL Pharma is 7.2x. |
| Is EQL Pharma profitable? | Yes, EQL Pharma is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of EQL Pharma? | EQL Pharma's last 12 months EBITDA is $8.8M. |
| What is EQL Pharma's EBITDA margin? | EQL Pharma's last 12 months EBITDA margin is 22%. |
| What is the current EV/EBITDA multiple of EQL Pharma? | Current EBITDA multiple of EQL Pharma is 33.1x. |
| What is the current FCF of EQL Pharma? | EQL Pharma's last 12 months FCF is -$23.1M. |
| What is EQL Pharma's FCF margin? | EQL Pharma's last 12 months FCF margin is -57%. |
| What is the current EV/FCF multiple of EQL Pharma? | Current FCF multiple of EQL Pharma is -12.7x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
